Truist Raises Price Target on Glaukos to $141 From $125, Maintains Buy Rating
Glaukos Analyst Ratings
Morgan Stanley Raises Price Target on Glaukos to $120 From $100, Keeps Equalweight Rating
Glaukos Analyst Ratings
Needham Raises Price Target on Glaukos to $131 From $113, Maintains Buy Rating
Glaukos Analyst Ratings
Glaukos Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Glaukos (GKOS) and Arcus Biosciences (RCUS)
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Perspective Therapeutics (CATX) and Glaukos (GKOS)
Glaukos Analyst Ratings
Glaukos Analyst Ratings
Buy Rating on Glaukos With Strong Growth Prospects for IDose and MIGS Market Share
JPMorgan Adjusts Price Target on Glaukos to $110 From $108, Maintains Overweight Rating
BTIG Sticks to Its Buy Rating for Glaukos (GKOS)
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), American Well (AMWL) and Glaukos (GKOS)
Buy Rating Affirmed for Glaukos on Strong Q1 Performance and Promising IDose Prospects
Glaukos Analyst Ratings
Glaukos Analyst Ratings
Glaukos Analyst Ratings
Glaukos Analyst Ratings